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ESMO Minimum Clinical Recommendations for diagnosis,
treatment and follow-up of newly diagnosed large cell
non-Hodgkin’s lymphoma
Incidence
. Large Cell Lymphoma constitutes 30–58% of non-Hodg-
kin’s lymphoma series. The crude incidence in the European
Union is 3–4/100 000 per year. The incidence increases
with age from 0.3/100 000 per year (35–39 y) to
26.6/100 000 per year (80–84 y).
Diagnosis
. Diagnosis should almost always be based on a surgical
specimen/excisional lymph node biopsy providing enough
material for fresh frozen and formalin-fixed samples. To
ensure adequate quality, immediate processing by an experi-
enced pathology institute has to be guaranteed.
. Fine needle aspirations or core biopsies may be appropriate
as the only diagnostic test in the rare patients requiring
emergency treatment or those not suitable for curative
therapy.
. The histological report should give the diagnosis according
to the WHO classification with use of CD20
immunohistochemistry.
Staging and risk assessment
. Patients amenable to curative therapy should have at least a
chest X-ray and a CT-scan of the abdomen, as well as a
bone marrow aspirate and biopsy. A diagnostic spinal tap
directly combined with a first prophylactic instillation of
cytarabine or methotrexate shall be considered in high-risk
patients [patients with more than two adverse parameters
according to international prognostic index (IPI)] with e.g.
involvement of bone marrow, testis, the spine, or the base
of the skull [V, D].
. A complete blood count, routine blood chemistry including
LDH and uric acid as well as a screening test for HIV and
hepatitis B and C are required. Protein electrophoresis is
recommended for B-cell lymphomas.
. The staging is given according to the Ann Arbor system
with mentioning of bulky disease [III, A]. For prognostic
purposes, the IPI should be established [III, A].
Treatment plan
. A multidisciplinary treatment planning is required:
Treatment with curative intent: CHOP-treatment combined
with rituximab given every 21 days for usually 8 cycles is
the current standard for CD20 + large-cell non-Hodgkin’s
lymphoma of all stages [II, A]. In T-cell lymphoma, CHOP
remains the standard. Shortening the interval between
CHOP cycles to two weeks with growth factor support may
be considered [II, B].
. High-dose chemotherapy with stem cell transplantation in
poor risk patients remains experimental.
. Consolidation by radiotherapy to sites of bulky disease has
not proven its benefit [III, C].
. Dose reductions due to hematological toxicity should be
avoided and febrile neutropenia justifies prophylactic use of
hematopoietic growth factors in patients treated with cura-
tive intent.
Response evaluation
. Adequate radiological tests should be done after 2 to 4
cycles and after the last cycle of CHOP or CHOP + radio-
therapy, and whenever there are doubts regarding adequate
response.
. An initially pathologic bone marrow aspirate/biopsy or
spinal tap should be repeated at the end of treatment.
. Patients with incomplete or lacking response should be eval-
uated for early salvage regimens.
Follow-up
. History and physical examination every 3 months for 2
years, every 6 months for 3 more years, and then once a year
with attention to development of secondary tumors [V, D].
High-risk patients still with curative options, such as
high-dose chemotherapy with stem cell support, may
mandate more frequent controls.
. Blood count and LDH at 3, 6, 12, and 24 months, then only
as needed for evaluation of suspicious symptoms or clinical
findings in those patients suitable for further therapy [V, D].
. Evaluation of thyroid dysfunction (TSH) in patients with
irradiation to the neck at 1, 2, and at least at 5 years [III,
A].
. After having received chest irradiation at premenopausal
age, especially at an age below 25 years, women should be
screened for secondary breast cancers clinically [III, A] and,
after the age of 40–50 years, by mammography [III, C].
. Minimal adequate radiological examinations at 6, 12, and
24 months after end of treatment, by CT scan when indi-
cated by site of disease [V, D].
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Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts
and the ESMO faculty.
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